Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies.
There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.
The VANGUARD project aims to generate a vascularized and immune-protected bioartificial pancreas that can be transplanted into non-immuno-suppressed patients by combining advanced tissue engineering strategies.
This approach will yield a cell therapy in the form of an Advanced Therapy Medicinal Product (ATMP), which can significantly improve treatment of type 1 diabetes.
A new VANGUARD publication has recently been made available in Transplant International. Its name is “Ethics of Early Clinical Trials of Bio-Artificial Organs” and the
A new VANGUARD article has recently been published in Current Opinion in Endocrine and Metabolic Research. “Advances and challenges of endocrine pancreas bioengineering” – Islet
On June 3-4, the VANGUARD consortium finally met in person after two years of online meetings. The meeting, which took place at the Geneva University